Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
January 12, 2021 08:00 ET
|
Vir Biotechnology, Inc.
– First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research – FOSTER CITY, Calif. and SAN FRANCISCO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Gilead...